AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 72 min read$ANIP

CAREY STEPHEN P. sold $285K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 3,313 shares of ANI PHARMACEUTICALS INC (ANIP) at $86.00 ($0.28M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jul 7, 2026, 1:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ANIP
Neutral
medium confidence
Mentioned
$ANIP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

An SVP & CFO sold $284,918 worth of shares via an open-market sale under a pre-arranged 10b5-1 plan; no other company fundamentals are disclosed.

02

Market read

Traders may monitor for patterns in insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it reduces the informational content versus discretionary selling.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed July 6 for a July 2 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals (ANIP).

Company-level read

Ticker impact

$ANIPNeutralMedium confidence
Context

ANI Pharmaceuticals disclosed an SVP & CFO open-market sale of 3,313 shares at $86 on a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless paired with other new company-specific catalysts.

Evidence & confidence

Form 4 shows a planned open-market sale with no accompanying guidance, operational update, or transaction tied to a corporate event.

Market effects

Sector

Minimal—this is company-specific insider transaction data with no sector-wide regulatory/clinical/financing signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Some traders may read repeated insider selling as a bearish signal, especially if it coincides with other negative developments not mentioned here.

Key entities

  • issuer
    ANI Pharmaceuticals Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Carey Stephen P.

    SVP & CFO who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

SEP 4
$ANIPLow

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

ANI Pharmaceuticals (ANIP) appointed Henry Gosebruch to its board, replacing Muthusamy Shanmugam, who will remain in operational roles. Gosebruch has biotech leadership experience. The company, with a $1.6b market cap, develops and markets branded and generic drugs. Board changes may influence capital allocation and product mix.

finance.yahoo.com1 min
AUG 19
$ANIPMedAI 8/10

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.

aol.com6 min
AUG 14
$ANIPMedAI 8/10

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals reported Q2 2026 total net revenues of $266.0 million, up 25.9% year over year, and adjusted non-GAAP EBITDA of $71.6 million, up 32.4%. Cortrophin Gel revenues were $117.1 million (+43.5%). 2026 guidance: net revenue $1.08B-$1.14B, Cortrophin Gel $520M-$540M, adjusted EBITDA $285M-$300M, EPS $9.19-$9.69.

fool.com7 min